AstraZeneca success torpedoes PCI’s pivotal plan, crushing stocknews2022-01-25T11:23:03+00:00January 25th, 2022|FierceBiotech|
89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data setnews2022-01-24T19:51:24+00:00January 24th, 2022|FierceBiotech|
New clinical trial organization launches with promise to conduct randomized trials at fraction of the costnews2022-01-24T15:36:17+00:00January 24th, 2022|FierceBiotech|
1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trialnews2022-01-24T13:26:00+00:00January 24th, 2022|FierceBiotech|
MaaT wraps up cancer microbiome trial early to power into phase 2/3 this yearnews2022-01-24T12:13:01+00:00January 24th, 2022|FierceBiotech|
New research on tau’s role in neurodegenerative diseases like Alzheimer’s could inform new treatmentsnews2022-01-21T18:51:49+00:00January 21st, 2022|FierceBiotech|
Alnylam touts data replication for next-generation Onpattro in ATTR trial but analysts pour some cold waternews2022-01-21T15:40:56+00:00January 21st, 2022|FierceBiotech|
MD Anderson inks deal to put Chinese cancer drugs through trials, starting with a PI3K inhibitornews2022-01-21T13:00:49+00:00January 21st, 2022|FierceBiotech|
Kura exits FDA clinical hold after agreeing to mitigation measures, enabling resumption of blood cancer trial news2022-01-21T11:37:02+00:00January 21st, 2022|FierceBiotech|
CROs embracing tech to decentralize trials and speed enrollment as regulators show support ‘with their feet’news2022-01-20T13:54:28+00:00January 20th, 2022|FierceBiotech|
